April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Evaluating Intravitreal Nanoparticles as a Potential New System for the Sustained Treatment of Degenerative and Proliferative Diseases of the Retina
Author Affiliations & Notes
  • P. J. McDonnell, III
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Y. A. Khan
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • S. K. Lai
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • R. T. Kashiwabuchi
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • W. Tattiyakul
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • A. Behrens
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • J. Hanes
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  P.J. McDonnell, III, None; Y.A. Khan, None; S.K. Lai, None; R.T. Kashiwabuchi, None; W. Tattiyakul, None; A. Behrens, None; J. Hanes, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 432. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. J. McDonnell, III, Y. A. Khan, S. K. Lai, R. T. Kashiwabuchi, W. Tattiyakul, A. Behrens, J. Hanes; Evaluating Intravitreal Nanoparticles as a Potential New System for the Sustained Treatment of Degenerative and Proliferative Diseases of the Retina. Invest. Ophthalmol. Vis. Sci. 2010;51(13):432. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Intravitreal injection of angiogenesis inhibitors has become commonplace in the treatment of retinal diseases, such as age related macular degeneration and proliferative diabetic retinopathy. Unfortunately, this route of delivery requires repeated injections, increasing the risk of infection and retinal injury. The purpose of this study is to determine the length of time nanoparticles can be retained in the vitreous chamber after pars plana injection, and to explore the possible use of these drug carriers for long term treatment of diseases of the retina.

Methods: : This study was conducted on 9 rabbit eyes and included 3 groups. The control group received a 100 µL intravitreal injection of saline, the Uncoated group received 100 µL of intravitreal 200 nm uncoated latex particle solution, and the Coated group received 100 µL of intravitreal 200 nm latex particles coated with a polymer to prevent aggregation. The baseline fluorescence and intraocular pressures (IOP) were assessed prior to injection through the pars plana. The particles were fluorescence tagged and assessment of retention was made by analysis of in vivo fluorescence imaging. Images and IOP measurements were obtained at 0 min, 1 hr, daily for 1 week and every 5 days for one month. The fluorescence images from each time point were compared to those obtained immediately after the intravitreal injection to determine the relative retention rates for each eye.

Results: : There was no significant difference between the clearance profiles of the coated and uncoated particles; and there was no significant decline in the particles retained in the vitreous chambers in 30 days. (P<0.05) There was no detectable fluorescence signal in the control group. There were no changes in IOP in any group.

Conclusions: : Nanoparticles, which can offer sustained and predictable release of medications, may be an effective system for long-term intravitreal drug delivery and the treatment of various retinal diseases.

Keywords: retina • vitreous • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×